gopubmed logo
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Aug 2016.

IKAROS family zinc finger 3

AIO, Aiolos
This gene encodes a member of the Ikaros family of zinc-finger proteins. Three members of this protein family (Ikaros, Aiolos and Helios) are hematopoietic-specific transcription factors involved in the regulation of lymphocyte development. This gene product is a transcription factor that is important in the regulation of B lymphocyte proliferation and differentiation. Both Ikaros and Aiolos can participate in chromatin remodeling. Regulation of gene expression in B lymphocytes by Aiolos is complex as it appears to require the sequential formation of Ikaros homodimers, Ikaros/Aiolos heterodimers, and Aiolos homodimers. At least six alternative transcripts encoding different isoforms have been described. [provided by RefSeq, Jul 2008] (from NCBI)
Top mentioned proteins: Ikaros, Helios, CAN, V1a, HAD
Papers on AIO
Ikaros, Helios, and Aiolos protein levels increase in human thymocytes after β selection.
Yankee et al., Kansas City, United States. In Immunol Res, Jan 2016
We then analyzed protein levels of Ikaros, Helios, and Aiolos, the three Ikaros family members most abundantly expressed in human thymocytes.
Impact of Subsequent Therapies on Outcome of the FIRE-3/AIO KRK0306 Trial: First-Line Therapy With FOLFIRI Plus Cetuximab or Bevacizumab in Patients With KRAS Wild-Type Tumors in Metastatic Colorectal Cancer.
Heinemann et al., Mainz, Germany. In J Clin Oncol, Dec 2015
PURPOSE: We investigated choice and efficacy of subsequent treatment, with special focus on second-line therapy, in the FIRE-3 trial (FOLFIRI plus cetuximab [arm A] or bevacizumab [arm B]) for patients with KRAS wild-type metastatic colorectal cancer.
Overexpression of Aiolos in Peripheral Blood Mononuclear Cell Subsets from Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis.
Jiang et al., Shenyang, China. In Biochem Genet, Dec 2015
UNASSIGNED: Genetic studies demonstrate that the Aiolos polymorphisms contribute to the susceptibility to autoimmune diseases.
First-Line Treatment of Metastatic Colorectal Cancer: Interpreting FIRE-3, PEAK, and CALGB/SWOG 80405.
Tabernero et al., Barcelona, Spain. In Curr Treat Options Oncol, Nov 2015
Three studies, the phase III FIRE-3 (AIO KRK-0306), the phase II PEAK, and the recently presented phase III CALGB/SWOG 80405 trial, have addressed this issue face-on, directly comparing the addition of bevacizumab versus cetuximab or panitumumab to FOLFOX/FOLFIRI in terms of efficacy outcomes.
The IMiDs targets IKZF-1/3 and IRF4 as novel negative regulators of NK cell-activating ligands expression in multiple myeloma.
Cippitelli et al., Roma, Italy. In Oncotarget, Oct 2015
Depletion of cereblon (CRBN) by shRNA interference strongly impaired upregulation of these ligands and, more interestingly, IMiDs/CRBN-mediated downregulation of the transcription factors Ikaros (IKZF1), Aiolos (IKZF3) and IRF4 was critical for these regulatory mechanisms.
Harnessing the Therapeutic Potential of Th17 Cells.
Mageed et al., Arbīl, Iraq. In Mediators Inflamm, 2014
For development, Th17 cells require activation of the transcription factors STAT3 and RORγt while RUNX1, c-Maf, and Aiolos are involved in changes of phenotype/functions.
Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4.
Thakurta et al., Summit, United States. In Blood Cancer J, 2014
Recent discoveries suggest that the critical events leading to the anti-proliferative activity of the IMiD immunomodulatory agents lenalidomide and pomalidomide in multiple myeloma (MM) cells are initiated by Cereblon-dependent ubiquitination and proteasomal degradation of substrate proteins Ikaros (IKZF1) and Aiolos (IKZF3).
Anti-EGFR MoAb treatment in colorectal cancer: limitations, controversies, and contradictories.
Qian et al., Nanjing, China. In Cancer Chemother Pharmacol, 2014
Moreover, WHO or RECIST guideline for response assessment in anti-EGFR MoAb treatment was also queried by recent AIO KRK-0306 trial.
The wind god promotes lung cancer.
Schaller et al., Morgantown, United States. In Cancer Cell, 2014
In this issue of Cancer Cell, Li and colleagues demonstrate that the hematopoietic transcription factor Aiolos (named after the Wind God of Greek mythology) confers anoikis resistance in lung tumor cells through repression of cell adhesion-related genes including the mechanosensor p66Shc.
Aiolos promotes anchorage independence by silencing p66Shc transcription in cancer cells.
Liu et al., Tianjin, China. In Cancer Cell, 2014
Here we find that a lymphocyte lineage-restricted transcription factor, Aiolos, is frequently expressed in lung cancers and predicts markedly reduced patient survival.
Stage-specific control of early B cell development by the transcription factor Ikaros.
Busslinger et al., Vienna, Austria. In Nat Immunol, 2014
Unexpectedly, derepression of expression of the transcription factor Aiolos did not compensate for the loss of Ikaros in pro-B cells.
From anecdote to targeted therapy: the curious case of thalidomide in multiple myeloma.
Johnstone et al., Chicago, United States. In Cancer Cell, 2014
These agents bind to cereblon, a component of a ubiquitin ligase complex, altering the specificity of the complex to induce the ubiquitylation and degradation of Ikaros (IKZF1) and Aiolos (IKZF3), transcription factors essential for MM growth.
Aiolos promotes TH17 differentiation by directly silencing Il2 expression.
Kuchroo et al., Boston, United States. In Nat Immunol, 2012
study demonstrated that Aiolos silenced the Il2 locus, promoting TH17 differentiation in vitro and in vivo
17q12-21 variants are associated with asthma and interact with active smoking in an adult population from the United Kingdom.
Simpson et al., Manchester, United Kingdom. In Ann Allergy Asthma Immunol, 2012
Sixteen SNPs were significantly associated with asthma of which one SNP was novel (IKZF3-rs1453559).
Management of localized gastrointestinal stromal tumors and adjuvant therapy with imatinib.
del Muro et al., A Coruña, Spain. In Anticancer Drugs, 2012
A significant number of phase II studies have shown that 1 year of adjuvant therapy with 400 mg/day imatinib significantly reduces the recurrence of GISTs following surgery and extends recurrence-free survival, with evidence from the SSGXVIII/AIO study showing that extending the duration of adjuvant therapy to 3 years further increases recurrence-free and overall survival.
Identification of IRF8, TMEM39A, and IKZF3-ZPBP2 as susceptibility loci for systemic lupus erythematosus in a large-scale multiracial replication study.
GENLES Network et al., Oklahoma City, United States. In Am J Hum Genet, 2012
Four additional susceptibility loci (IRF8, TMEM39A, IKZF3, and ZPBP2) for systemic lupus erythematosus were robustly established a multiethnic population (European, African American, Asian, Hispanic, Gullah, and Amerindian).
Biomarkers of anti-angiogenic therapy in metastatic colorectal cancer (mCRC): original data and review of the literature.
Reinacher-Schick et al., Bochum, Germany. In Z Gastroenterol, 2011
We investigated several potential predictive anti-angiogenic markers including circulating endothelial progenitor cells (EPC) in patients with mCRC receiving bevacizumab containing treatment within a randomised multicenter phase 2 study of the German AIO GI tumour study group.
Biomarkers and pharmacogenetics in pancreatic cancer. Highlights from the "2011 ASCO Annual Meeting". Chicago, IL, USA; June 3-7, 2011.
Saif et al., New York City, United States. In Jop, 2011
In the 2011 American Society of Clinical Oncology (ASCO) Annual Meeting, researchers have presented several interesting results in biomarkers development: the identifications of 9 single nucleotide polymorphisms (SNPs) that is associated with positive efficacy of gemcitabine (Abstract #4022); the introduction of circulating tumor cells as a prognostic markers in pancreatic adenocarcinoma (Abstract #e14657); the re-affirmation of plasma cytidine deaminase (CDA) as a positive predictive markers for gemcitabine efficacy, as well as the postulations that CDA*3 as a potential genotype marker to predict gemcitabine responses (Abstract #e14645); and finally the retrospective tumor tissues analysis in the Arbeitsgemeinschaft Internistische Onkologie (AIO) trial in an attempt for epidermal growth factor receptor (EGFR) pathway biomarker identifications (Abstract #4047).
Deregulation of Aiolos expression in chronic lymphocytic leukemia is associated with epigenetic modifications.
Rebollo et al., Paris, France. In Blood, 2011
To determine the consequences of Aiolos deregulation in B-CLL, we analyzed the effects of Aiolos overexpression or down-regulation on apoptosis.
Ikaros and Aiolos inhibit pre-B-cell proliferation by directly suppressing c-Myc expression.
Lu et al., Omaha, United States. In Mol Cell Biol, 2010
Aiolos and Ikaros bind to the c-myc promoter in vivo and directly suppress c-myc expression in pre-B cells.
share on facebooktweetadd +1mail to friends